TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02342496

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active, only probiotics
Description: Powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active, blend of berries and probiotics
Description: Powder
Study: NCT00670501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Supplement
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Supplement
Description: Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplement
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplement
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D Supplement
Description: Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
Study: NCT04726384

Intervention type: DEVICE
Intervention: Assessment of physical activity level
Description: Physical activity was assessed using the Sensewear Armband device. Patients received the device on Thursday mornings, prior to exercise and treatments. The device was placed on the right arm throughout the study. Patients in whom the device monitored a minimum of 95% of the time of the study day were analyzed. Prior to the study, the devices were programmed to record a minimum level of intense (\>3MET) and moderate ( \>6MET) exercise.
Study: NCT02508051

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Article email links
Description: Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blog email links
Description: Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
Study: NCT04192851

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tent Pole Technique
Description: * All patients were operated under local or general anaesthesia according to the case and patient tolerability.~* The oral cavity was prepared by 0.12% chlorhexidine mouthrinses solution\* for thirty seconds.~* Full thickness incision down to the bone with blade no.15.~* A periosteal elevator was used to perform mucoperiosteal flap.~* Gentle elevation of the flap~* Fixation of the screws over the alveolar ridge with about 5 mm of the screw threads will be exposed~* Bone graft was mixed with the patient blood and placed to cover the screws completely.~* PRF membrane was be placed over the grafted sites.~* Repositioning of the flap and suturing with 3/0 black silk suture material
Study: NCT04498169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic
Description: Netarsudil Ophthalmic Solution 0.02% Topical Sterile Ophthalmic Solution
Study: NCT00791258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine and olmesartan medoxomil tablets
Description: amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide tablets
Description: hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
Study: NCT03957395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Precision Novi™ system Neurostimulation procedures
Description: SCS with Device: Precision Novi™ system
Study: NCT00357214

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Bicarbonate
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: 67.5 mmol/d given as three tablets after each meal, with a full glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo (microcrystalline cellulose)
Description: Given as three tablets after each meal, with a full glass of water
Study: NCT04110548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Task
Description: Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Task
Description: Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craving Regulation Task
Description: Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand.
Study: NCT01789762

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous plasma
Description: Transfusions of platelet concentrates re-suspended in autologous plasma

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Additive solution
Description: Transfusions of platelets prepared in additive solution (Intersol)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pathogen reduction process
Description: Patients transfused with platelets treated by pathogen reduction process
Study: NCT02877862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mAGIC app
Description: 7-day app to encourage uptake of genetic counseling
Study: NCT03146767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetanus stabilization of baseline
Description: Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
Study: NCT04062019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10\~6 IU/m2 once every other day, for 3 months.
Study: NCT03801954

Intervention type: BEHAVIORAL
Intervention: Educational Videos
Description: 15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
Study: NCT04122404

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: LF-LAM
Description: Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
Study: NCT04722120

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low radiation dose CT
Description: Underwent liver CT with 30% lower radiation dose

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT (radiation)
Description: Underwent liver CT without change of radiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low contrast dose CT
Description: Underwent liver CT 20% lower dose contrast media.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CT (contrast agent)
Description: Underwent liver CT without change of contrast media doses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep-learning based contrast boosting algorithms
Description: Applied deep-learning based contrast boosting algorithms on acquired CT images
Study: NCT02677948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT01368536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valturna
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valturna
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
Study: NCT02757508

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: protein powder supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamins/minerals
Study: NCT01716234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 12 mg/kg/day BID
Description: Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 12 mg/kg/day BID
Description: Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day BID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day BID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day TID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 18 mg/kg/day TID
Description: Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole 12 mg/kg/day TID
Description: Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
Study: NCT06190704

Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.

Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Study: NCT03420599

Intervention type: PROCEDURE
Intervention: splenectomy
Description: Traumatic patients who performed total splenectomy
Study: NCT02779101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab 200 mg every 3 weeks
Study: NCT00516360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3.15% chlorhexidine as daily antiseptic on needleless access port
Description: 3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3.15% chlorhexidine as daily antiseptic on needleless access port
Description: 3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
Study: NCT04455256

Intervention type: OTHER
Intervention: x box binding protein
Description: Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.

Intervention type: OTHER
Intervention: x box binding protein
Description: Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.
Study: NCT01368536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valturna
Description: Valturna (aliskiren 150 mg/valsartan 160 mg) tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg and 10 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 15 mg and 25 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Valturna Tablet
Description: Matching placebo of valturna tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Valturna Tablet
Description: Matching placebo of valturna tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Valturna Tablet
Description: Matching placebo of valturna tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Capsule
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Capsule
Description: Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
Study: NCT03558165

Intervention type: DIAGNOSTIC_TEST
Intervention: Oncomine Comprehensive Assay
Description: Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
Study: NCT03410849

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: in both arms intervention 'gastroscopy' will be carried out

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: in both arms intervention 'gastroscopy' will be carried out
Study: NCT04188795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delirium Preventive Care Protocol
Description: Nursing care was applied to hip fracture patients in the experimental group in accordance with the care protocol developed to prevent delirium. Delirium preventive care protocol was consist of; psychosocial care, monitoring of oxygen saturation, prevention of dehydration, nutritional support, normal elimination, pain control, sleep regulation, avoidance of bladder catheterization and early mobilization.~Confusion Assessment Method, Barthel Index and Richards-Campbell Sleep Questionnaire were repeated to patients on the first postoperative day and on the third day.
Study: NCT04263064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Volume-Low Concentration without Clonidine
Description: The control for this study will be a High Volume-Low Concentration (1.5cc/kg of 0.15% ropivacaine and 5mcg/cc epinephrine) caudal block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Volume-Low Concentration with clonidine
Description: The study intervention will be High Volume-Low Concentration with clonidine (1.5cc/kg of 0.15% ropivacaine, with 1mcg/cc of clonidine and 5mcg/cc epinephrine).
Study: NCT02319668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% w/v Chlorhexidine digluconate
Description: Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride toothpaste (Aquafresh Mild & Minty)
Description: Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
Study: NCT00698724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom, and Optive
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xibrom and Pred Forte
Description: Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
Study: NCT02116504

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sampling of blood
Description: Sampling of blood for dosage of antibodies
Study: NCT00655954

Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Used Ultrasonic nebuliser

Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Used Ultrasonic nebuliser

Intervention type: PROCEDURE
Intervention: Induced sputum
Description: Used Ultrasonic nebuliser
Study: NCT02558114

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin

Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Study: NCT02150148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Mentored Gardening Intervention
Description: receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental: Mentored Gardening Intervention
Description: receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
Study: NCT00097747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study: NCT01495858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)
Description: Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium 440 mg (BAYH6689)
Description: Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPH 50 mg
Description: Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.